PubMed چکیده/رکورد

Molecular and clinicopathological characterisation of SMARCA4-deficient uterine tumours: distinguishing features between dedifferentiated/undifferentiated endometrial carcinoma and undifferentiated uterine sarcoma.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

SMARCA4-deficient uterine tumours encompass two distinct entities: SMARCA4-deficient undifferentiated/dedifferentiated endometrial carcinoma (SDUDEC) and SMARCA4-deficient uterine sarcoma (SDUS). Despite their divergent classifications, these tumours share overlapping clinicopathological and molecular features that complicate diagnosis. This study characterises their distinguishing features and clinical significance through analysis of 34 SDUDEC and 14 SDUS cases, integrating clinicopathological, immunohistochemical [BRG1 (encoded by SMARCA4), BRM (encoded by SMARCA2), INI1 (encoded by SMARCB1), ARID1A, ARID1B, SOX2, claudin-4, CK8/18, Chromogranin, synaptophysin, INSM1, p53, and MMR proteins], and next-generation sequencing (NGS; 14 SDUDEC and 14 SDUS) data. SDUDEC patients were significantly older than SDUS patients, with a median age of 54 years (range 28-63) compared to 37 years (range 24-58) (p<0.01). SDUDEC exhibited marked immunohistochemical heterogeneity, whereas SDUS showed uniform profiles: all SDUS cases (10/10) demonstrated dual BRG1/BRM loss with preserved expression of other SWI/SNF complex proteins, absent claudin-4 (0/12) and SOX2 (0/8) expression, and no MMR deficiency (0/14) or mutant-type p53 (0/13). NGS revealed frequent endometrial carcinoma-associated alterations in SDUDEC but rarely in SDUS. Prognostic outcomes did not differ significantly (p>0.05). These findings highlight distinct molecular landscapes: SDUDEC aligns with endometrial carcinogenesis, while SDUS may arise via alternative SMARCA4-dependent mechanisms. A diagnostic algorithm combining endometrial carcinoma molecular classification, SWI/SNF protein testing, and thorough sampling is proposed. This study expands the clinicopathological and molecular spectrum of SMARCA4-deficient uterine tumours, underscoring the need for entity-specific management strategies.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

SMARCA4-deficient undifferentiated and dedifferentiated endometrial carcinoma (SDUDEC)SMARCA4-deficient uterine sarcoma (SDUS)SMARCA4-deficient uterine tumoursclinicopathological and molecular characteristicsdifferential diagnosis
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort.

BACKGROUND: Urine cytology is recommended for noninvasive detection of urothelial carcinoma (UC) but shows limited sensitivity, particularly in low-grade disease. Keratin 17 (K17) has emerged as a promising immunocytochemical marker. This study evaluated the diagnostic performance and interobserver agreement of K17 in a routine setting. METHODS: This prospective cross-sectional study included 184 urine samples from patients undergoing …

PubMed2026

A case report of primary prostate intravascular large B-cell lymphoma.

RATIONALE: Primary intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive extranodal lymphoma that rarely affects the prostate. Its nonspecific clinical and laboratory features often lead to misdiagnosis as benign prostatic hyperplasia (BPH) or prostatitis, delaying appropriate treatment. We report a case of primary prostatic IVLBCL initially misdiagnosed as BPH, highlighting the diagnostic challenges and the importance …

PubMed2026

An immunohistochemical based assessment of murine double minute 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) in jaw osteosarcoma and benign osseous lesions.

UNLABELLED: The diagnosis of primary bone tumours of the jaw often presents as a diagnostic dilemma. Overlap in clinical, radiological, and histological features between benign lesions like juvenile trabecular ossifying fibroma (JTOF); osteoblastoma (OB) and malignant tumours like low-grade osteosarcoma (LGOS) makes the diagnosis challenging. While osteosarcoma is a malignant tumour with poor prognosis requiring aggressive treatment, b…

PubMed2026

The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer.

PURPOSE: The antibody-drug conjugates (ADCs) sacituzumab govitecan (SG) and datopotamab deruxtecan target trophoblast cell surface antigen 2 (TROP-2) and have shown significant efficacy in HER2-negative metastatic breast cancer (mBC). As TROP-2 may serve as a target across multiple treatment lines, detailed information on TROP-2 expression over time is of great interest. METHODS: TROP-2 expression was analyzed in breast cancer (BC) sam…